Results 121 to 130 of about 16,167 (200)

A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure [PDF]

, 2018
Erik Nilsson, Pietro de Deco, Marco Trevisan, Rino Bellocco, Bengt Lindholm, Lars H. Lund, Josef Coresh, Juan Jesús Carrero   +7 more
openalex   +1 more source

Efficacy and safety of mineralocorticoid receptor antagonists in kidney transplant patients: an updated meta-analysis of randomized controlled trials. [PDF]

BMC Nephrol
Dibo P, Mareddy NSR, Kojima GSA, Ershed M, Obi OS, Razaq S, Kumar V.   +6 more
europepmc   +1 more source

Mineralocorticoid receptor antagonists in kidney transplantation: time to consider? [PDF]

, 2018
Sophie Girerd, Frédéric Jaisser
openalex   +1 more source

Initiation of SGLT2 inhibitors versus mineralocorticoid receptor antagonists as third-line therapy in heart failure with reduced ejection fraction: a nationwide cohort study. [PDF]

Lancet Reg Health Eur
Svanström H, Mkoma GF, Hviid A, Pasternak B.   +3 more
europepmc   +1 more source

#1589 Finerenone as a novel non-steroidal mineralocorticoid receptor antagonist: a potential therapeutic option for lupus nephritis [PDF]

Mingfang Sun
openalex   +1 more source

Comparing the Long-Term Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors Versus Mineralocorticoid Receptor Antagonists as Add-On Therapies in the Management of Heart Failure: A Systematic Review. [PDF]

Cureus
George V, Pillai MH, Jacob V, Mp R, Vasant A, Adnan H.   +5 more
europepmc   +1 more source

Angiotensin converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists and SARS-CoV-2 infection

, 2020
Pratiksha Valera, Pheletso Letuka, Nontobeko Mathenjwa, Ntobeko Ntusi   +3 more
openalex   +2 more sources

Will mineralocorticoid receptor antagonists give impact on HFpEF pharmacotherapy in addition to SGLT2 inhibitors? [PDF]

Eur Heart J Cardiovasc Pharmacother
Komiyama M, Hasegawa K, Rosano GMC.
europepmc   +1 more source

Aldosterone-Related Cardiovascular Disease and Benefits of Mineralocorticoid Receptor Antagonists in Clinical Practice. [PDF]

JACC Adv
Alfarano M, Marchionni G, Costantino J, Ballatore F, Verardo R, Miraldi F, Ciciarello FL, Petramala L, Letizia C, Frustaci A, Chimenti C.   +10 more
europepmc   +1 more source

Cardiovascular Outcomes and Hyperkalemia Risk in Patients With Diabetes, Chronic Kidney Disease and Heart Failure: A Real-World Comparison of Non-steroidal versus Steroidal Mineralocorticoid Receptor Antagonists. [PDF]

Cureus
Okunlola AO, Kolawole O, Otabor E, Hassan A, Hamilton M, Alomari L, Lam J, Idowu AB.   +7 more
europepmc   +1 more source